HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (18)
  • Publications (16)
  • References (21)
  • Uncategorized (6)
  • Video (1)

Recent Posts

December 4, 2025

HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting

by PJWCreative
Post placeholder image
November 9, 2025

SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

by HighField Bio
Post placeholder image
November 9, 2025

SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

by HighField Bio
October 31, 2025

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

by HighField Bio
Post placeholder image
July 31, 2025

Video 1 Test

by PJWCreative
April 21, 2025

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

by HighField Bio

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
September 30, 2020 in References

When liposomes met antibodies: Drug delivery and beyond

PJWCreative 0 Like Post Comments Off on When liposomes met antibodies: Drug delivery and beyond
Read More
Post placeholder image
September 9, 2020 in Publications

Advanced Drug Delivery Reviews: When Liposomes Met Antibodies: Drug Delivery and Beyond

PJWCreative 0 Like Post Comments Off on Advanced Drug Delivery Reviews: When Liposomes Met Antibodies: Drug Delivery and Beyond
Read More
Post placeholder image
September 3, 2020 in Publications

When liposomes met antibodies: Drug delivery and beyond

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
June 24, 2020 in References

A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
March 2, 2020 in Publications

Asian Journal of Pharmaceutical Sciences: Oral Uptake and Persistence of the FnAb-8 Protein Characterized by In Situ Radio-labeling and PET/CT Imaging

PJWCreative 0 Like Post Comments Off on Asian Journal of Pharmaceutical Sciences: Oral Uptake and Persistence of the FnAb-8 Protein Characterized by In Situ Radio-labeling and PET/CT Imaging
Read More
Post placeholder image
September 28, 2019 in References

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
November 30, 2018 in References

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
November 2, 2018 in Publications

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
October 26, 2018 in References

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
July 1, 2018 in Publications

Molecular Cancer Therapeutics: Selective Targeting and Eradication of LGR5+ Cancer Stem Cells Using RSPO-Conjugated Doxorubicin Liposomes

PJWCreative 0 Like Post Comments Off on Molecular Cancer Therapeutics: Selective Targeting and Eradication of LGR5+ Cancer Stem Cells Using RSPO-Conjugated Doxorubicin Liposomes
Read More
Prev1…34567Next

Download Company Profile

Home
Platforms
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin

© 2023-25 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文